 - Patients must have histologically documented adenocarcinoma of the prostate with progressive systemic clinically metastatic disease documented on bone, CT or MRI scan disease despite castrate levels of testosterone due to orchiectomy or LHRH agonist; castrate levels of testosterone must be maintained 